Most Read

According to the agreements, MS Pharma will oversee the registration, marketing along with the distribution of vedolizumab (PB016), ocrelizumab (PB018), and guselkumab (PB019) throughout MENA. Polpharma Biologics will

Genentech will obtain rights for OMass’ preclinical oral small molecule programme for IBD, as part of the agreement. OMass Therapeutics CEO Ros Deegan said: “Using our OdyssION platform,

This new dosing option enables patients with mild cognitive impairment or mild dementia to receive treatment at home, following an initial intravenous (IV) administration. Leqembi Iqlik, administered through

This is a rare and aggressive form of cancer for which there is no approved treatment currently. Aldeyra president and CEO Todd Brady said: “Primary vitreoretinal lymphoma is

This round of financing was led by SV Health Investors’ Dementia Discovery Fund (DDF), with contributions from existing investors including Newpath Partners, OrbiMed, Euclidean Capital, Chugai Venture Fund,

This change eliminates the previous requirement for a cardiovascular disease diagnosis prior to treatment. Amgen global commercial operations executive vice president Murdo Gordon said: “Far too many adults

The investment equips NewAmsterdam Pharma with the commercial capability to produce a fixed dose combination (FDC) of obicetrapib and ezetimibe, thereby addressing potential market demand. Piramal Pharma Solutions

Brukinsa’s recommended dose remains 320mg a day. The new tablets, each 160mg, allow patients to halve their intake of daily pill from four to two. Moreover, these tablets

Additionally, this combination is approved for the treatment of unresectable or advanced hepatocellular carcinoma (HCC). The approval introduces a dual immunotherapy option for two difficult-to-treat gastrointestinal cancers. Evidence